Therapeutic strategies targeting the epidermal growth factor receptor signaling pathway in metastatic colorectal cancer

被引：0
作者：
Zhou, Yi [1 ]
Wu, Shuang [1 ]
Qu, Fan-Jie [1 ]
机构：
[1] Dalian Med Univ, Affiliated Dalian Peoples Hosp 3, Dept Oncol, 40 Qianshan Rd, Dalian 116033, Liaoning, Peoples R China
来源：
WORLD JOURNAL OF GASTROINTESTINAL ONCOLOGY | 2024年 / 16卷 / 06期
关键词：
Metastatic colorectal cancer; Epidermal growth factor receptor; B-type RAF mutation; Kirsten rat sarcoma viral oncogene wild type; Kirsten rat sarcoma viral oncogene G12C mutation; Human epidermal growth factor receptor 2 overexpression/ amplification; FOLFIRI PLUS BEVACIZUMAB; 1ST-LINE TREATMENT; WILD-TYPE; OPEN-LABEL; SUBGROUP ANALYSES; COMBINED BRAF; CETUXIMAB; INHIBITION; CHEMOTHERAPY; PHASE-3;
D O I：
10.4251/wjgo.v16.i6.2362
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
More than 1.9 million new colorectal cancer (CRC) cases and 935000 deaths were estimated to occur worldwide in 2020, representing about one in ten cancer cases and deaths. Overall, colorectal ranks third in incidence, but second in mortality. More than half of the patients are in advanced stages at diagnosis. Treatment options are complex because of the heterogeneity of the patient population, including different molecular subtypes. Treatments have included conventional fluorouracil-based chemotherapy, targeted therapy, immunotherapy, etc. In recent years, with the development of genetic testing technology, more and more targeted drugs have been applied to the treatment of CRC, which has further prolonged the survival of metastatic CRC patients.
引用
收藏
页码：2362 / 2379
页数：19
相关论文
共 94 条
  • [1] Intermittent versus continuous oxaliplatin and fluoropyrimidine combination chemotherapy for first-line treatment of advanced colorectal cancer: results of the randomised phase 3 MRC COIN trial
    Adams, Richard A.
    Meade, Angela M.
    Seymour, Matthew T.
    Wilson, Richard H.
    Madi, Ayman
    Fisher, David
    Kenny, Sarah L.
    Kay, Edward
    Hodgkinson, Elizabeth
    Pope, Malcolm
    Rogers, Penny
    Wasan, Harpreet
    Falk, Stephen
    Gollins, Simon
    Hickish, Tamas
    Bessell, Eric M.
    Propper, David
    Kennedy, M. John
    Kaplan, Richard
    Maughan, Timothy S.
    [J]. LANCET ONCOLOGY, 2011, 12 (07) : 642 - 653
  • [2] Vemurafenib in Multiple Nonmelanoma Cancers with BRAF V600 Mutations
    Hyman, David M.
    Puzanov, Igor
    Subbiah, Vivek
    Faris, Jason E.
    Chau, Ian
    Blay, Jean-Yves
    Wolf, Juergen
    Raje, Noopur S.
    Diamond, Eli L.
    Hollebecque, Antoine
    Gervais, Radj
    Elena Elez-Fernandez, Maria
    Italiano, Antoine
    Hofheinz, Ralf-Dieter
    Hidalgo, Manuel
    Chan, Emily
    Schuler, Martin
    Lasserre, Susan Frances
    Makrutzki, Martina
    Sirzen, Florin
    Veronese, Maria Luisa
    Tabernero, Josep
    Baselga, Jose
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2015, 373 (08) : 726 - 736
  • [3] First-line mFOLFOX plus cetuximab followed by mFOLFOX plus cetuximab or single-agent cetuximab as maintenance therapy in patients with metastatic colorectal cancer: Phase II randomised MACRO2 TTD study
    Aranda, E.
    Garcia-Alfonso, P.
    Benavides, M.
    Sanchez Ruiz, A.
    Guillen-Ponce, C.
    Safont, M. J.
    Alcaide, J.
    Gomez, A.
    Lopez, R.
    Manzano, J. L.
    Mendez Urena, M.
    Sastre, J.
    Rivera, F.
    Gravalos, C.
    Garcia, T.
    Martin-Valades, J. I.
    Falco, E.
    Navalon, M.
    Gonzalez Flores, E.
    Garcia Tapiador, A. Ma
    Lopez Munoz, A. Ma
    Barrajon, E.
    Reboredo, M.
    Garcia Teijido, P.
    Viudez, A.
    Cardenas, N.
    Diaz-Rubio, E.
    [J]. EUROPEAN JOURNAL OF CANCER, 2018, 101 : 263 - 272
  • [4] Her2 activation mechanism reflects evolutionary preservation of asymmetric ectodomain dimers in the human EGFR family
    Arkhipov, Anton
    Shan, Yibing
    Kim, Eric T.
    Dror, Ron O.
    Shaw, David E.
    [J]. ELIFE, 2013, 2
  • [5] Prognostic and predictive value of primary tumour side in patients with RAS wild-type metastatic colorectal cancer treated with chemotherapy and EGFR directed antibodies in six randomized trials
    Arnold, D.
    Lueza, B.
    Douillard, J. -Y.
    Peeters, M.
    Lenz, H. -J.
    Venook, A.
    Heinemann, V.
    Van Cutsem, E.
    Pignon, J. -P.
    Tabernero, J.
    Cervantes, A.
    Ciardiello, F.
    [J]. ANNALS OF ONCOLOGY, 2017, 28 (08) : 1713 - 1729
  • [6] Mutations of KRAS and BRAF in primary and matched metastatic sites of colorectal cancer
    Artale, Salvatore
    Sartore-Bianchi, Andrea
    Veronese, Silvio Marco
    Gambi, Valentina
    Sarnataro, Carolina Silvia
    Gambacorta, Marcello
    Lauricella, Calogero
    Siena, Salvatore
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (25) : 4217 - 4219
  • [7] Therapeutic landscape and future direction of metastatic colorectal cancer
    Bando, Hideaki
    Ohtsu, Atsushi
    Yoshino, Takayuki
    [J]. NATURE REVIEWS GASTROENTEROLOGY & HEPATOLOGY, 2023, 20 (05) : 306 - 322
  • [8] An empirical review on the resistance mechanisms of epidermal growth factor receptor inhibitors and predictive molecular biomarkers in colorectal cancer
    Bhattacharya, Sankha
    [J]. CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2023, 183
  • [9] Efficacy according to biomarker status of cetuximab plus FOLFOX-4 as first-line treatment for metastatic colorectal cancer: the OPUS study
    Bokemeyer, C.
    Bondarenko, I.
    Hartmann, J. T.
    de Braud, F.
    Schuch, G.
    Zubel, A.
    Celik, I.
    Schlichting, M.
    Koralewski, P.
    [J]. ANNALS OF ONCOLOGY, 2011, 22 (07) : 1535 - 1546
  • [10] Location of colon cancer (right-sided versus left-sided) as a prognostic factor and a predictor of benefit from cetuximab in NCIC CO.17
    Brule, S. Y.
    Jonker, D. J.
    Karapetis, C. S.
    O'Callaghan, C. J.
    Moore, M. J.
    Wong, R.
    Tebbutt, N. C.
    Underhill, Cr.
    Yip, D.
    Zalcberg, J. R.
    Tu, D.
    Goodwin, R. A.
    [J]. EUROPEAN JOURNAL OF CANCER, 2015, 51 (11) : 1405 - 1414
12345678910